ArQule Gets a New CEO

Wade Roush4/15/08

Woburn, MA-based ArQule, which is developing several compounds known as kinase inhibitors as potential cancer therapies, said today that Paolo Pucci, a Bayer senior vice president overseeing Bayer-Schering’s global oncology and  therapeutics business, will take over as the company’s new CEO. Pucci succeeds Stephen Hill, a nine-year veteran of the company who announced his approaching departure in January and left ArQule to become president and CEO of Brussels, Belgium-based Solvay Pharmaceuticals on April 1.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can subscribe to his Google Group or e-mail him at wroush@xconomy.com. Follow @